Fiche publication
Date publication
octobre 2021
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi
Tous les auteurs :
Kasi A, Dotan E, Poage GM, Catteau A, Vernerey D, George M, Barzi A
Lien Pubmed
Résumé
Adjuvant chemotherapy use in stage II colon cancer is controversial. Current prognostic risk factors do not take the tumor immune microenvironment into account. Consideration of the Immunoscore, which measures the host immune response at the tumor site, may assist clinicians in reducing adjuvant chemotherapy use in patients who are unlikely to benefit from it. This study sought to determine the potential clinical utility of the Immunoscore, via its effect on medical oncologists' recommendations for management of patients with stage II colon cancer.
Mots clés
colonic neoplasms, oncologists, prognosis, surveys and questionnaires, tumor microenvironment
Référence
Cancers (Basel). 2021 Oct 30;13(21):
